---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-24-000073"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T22:15:37.229006+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics Q1 net loss $47.0M; bexotegrast adaptive Phase 2b/3 accelerated

## Summary
- Net loss $47.0M in Q1 2024 vs $37.5M in Q1 2023; R&D expenses rose to $37.1M from $29.3M.
- BEACON-IPF Phase 2b/3 adaptive design upsized to 360 patients; enrollment completion expected Q1 2025.
- Phase 2a PET imaging trial completed; topline data on total lung collagen and FVC expected in weeks.
- Oxford loan facility upsized by $50M to $150M; $30M drawn. Cash $483.9M funded through 2026.
- Regulatory clearance for PLN-101325 Phase 1 in muscular dystrophy; Phase 1 of PLN-101095 in solid tumors ongoing.

## SEC filing metadata
- accession: 0001746473-24-000073
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647324000073/0001746473-24-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647324000073/plrx-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-24-000073
- JSON: https://secwatch.observer/filing/0001746473-24-000073.json
- Plain text: https://secwatch.observer/filing/0001746473-24-000073.txt

## Key facts
- Earnings Releases
  PLIANT THERAPEUTICS, INC. reported first quarter ended March 31, 2024 results: net income Net loss of $47.0 million.
  - Period: first quarter ended March 31, 2024
  - Net income: Net loss of $47.0 million
  - Result: reported results
  source text: Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746473/000174647324000073/0001746473-24-000073-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.